Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "immunotherapies"

42 News Found

Takeda to acquire GammaDelta Therapeutics
Biotech | October 29, 2021

Takeda to acquire GammaDelta Therapeutics

The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies

Boehringer Ingelheim acquires Abexxa Biologics to advance its cancer research
Biotech | September 22, 2021

Boehringer Ingelheim acquires Abexxa Biologics to advance its cancer research

The addition of Abexxa’s expertise complements Boehringer Ingelheim’s current approaches to the treatment of difficult-to-treat solid cancers and especially those resistant to available immunotherapies

Latest Stories

USFDA issues Form 483 with 6 observations to Enzene Biosciences’ Chakan plant following PAI

Lupin partners with Spektus Pharma to commercialize DeslaFlex antidepressant in Canada

Sanofi Healthcare expands Hyderabad Global Hub, boosts capacity to 4,500 staff

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging